APA (7th ed.) Citation

C, L., RA, M., MJ, L., S, L., N, S., S, R., . . . F, K. (2026). Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. Journal for immunotherapy of cancer, 14(3), . https://doi.org/10.1136/jitc-2025-014365

Chicago Style (17th ed.) Citation

C, Li, et al. "Phase II Study of Olaparib and Durvalumab in Patients with Metastatic Castration-resistant Prostate Cancer." Journal for Immunotherapy of Cancer 14, no. 3 (2026). https://doi.org/10.1136/jitc-2025-014365.

MLA (9th ed.) Citation

C, Li, et al. "Phase II Study of Olaparib and Durvalumab in Patients with Metastatic Castration-resistant Prostate Cancer." Journal for Immunotherapy of Cancer, vol. 14, no. 3, 2026, https://doi.org/10.1136/jitc-2025-014365.